Target
CD3ε
1 abstract
Abstract
Phase I trial of chimeric anti-GPC3 scFv-CD3ε engineered T cells (CT0180) in patients with advanced hepatocellular carcinoma.Org: CARsgen Therapeutics Ltd., Co., Shanghai, China, CARsgen Therapeutics, CARsgen Therapeutics, Inc, Houston, TX,